Immutep (IMM.AX) drops to A$0.061 16 Mar 2026: heavy volume signals reprice

The IMM.AX stock closed at A$0.061 on 16 Mar 2026 after Immutep Limited confirmed a halt to a late-stage lung cancer trial. Trading was extremely active with 228,374,534 shares changing hands, far above the 10,168,881 average. The market closed with the ASX-listed biotechnology company sharply repriced, reflecting trial risk and fresh analyst downgrades. We look at financials, technicals, Meyka AI grading, and what the heavy volume means for short-term liquidity and longer-term value.

Price action and volume: IMM.AX stock today

IMM.AX stock opened at A$0.05, hit a high of A$0.069 and a low of A$0.05 before closing at A$0.061. The one-day change was -84.56%, a direct reaction to the trial discontinuation reported this week. Volume spiked to 228,374,534 shares, a relative volume of 42.57, indicating forced selling and rapid position reprice.

High volume on a tiny price base can compress bid depth and increase volatility. For traders on the ASX, this means execution risk is elevated and spreads will likely remain wide until order flow normalises.

Clinical setback and news flow driving IMM.AX stock moves

Immutep announced stopping a lung cancer trial for futility, triggering downgrades from analysts and a sharp share decline. Market coverage includes the trading reaction and analyst commentary; see recent coverage on Investing.com and company financial listings at Reuters.

Clinical trial outcomes are the primary value drivers for small biotech firms. The halt removes near-term value for Immutep’s lead asset and increases uncertainty over regulatory and partner timelines.

Fundamentals and valuation: where IMM.AX stock stands

Key metrics show a stretched valuation relative to cash and earnings. Immutep reports EPS -0.06, PE -0.75, and price-to-book 0.67. Market capitalisation is A$66,236,415 with 1,471,920,338 shares outstanding. The 50-day average price is A$0.3979 and the 200-day average is A$0.30753, both well above today’s close.

Balance-sheet ratios offer some cushion: current ratio 2.97 and cash per share A$0.0674. But high research spend (R&D to revenue ~603.71%) and negative free cash flow per share require future financing or partnerships to fund programs.

Technicals and trading outlook for IMM.AX stock

Technical indicators show no clear trend: RSI 52.31, ADX 13.40 and MACD near zero. Bollinger Bands centre at A$0.38 with upper A$0.41 and lower A$0.36, reflecting the prior price range before today’s event. Momentum oscillators show short-term relief levels, but order flow and news will dominate price action.

For most-active traders, watch support near the year low A$0.028 and intraday liquidity near A$0.05–A$0.07. Stop placement should account for thin bids and wide spreads.

Meyka AI grade and analyst consensus on IMM.AX stock

Meyka AI rates IMM.AX with a score out of 100. Meyka AI gives Immutep a score of 62.30, Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating data (dated 13 Mar 2026) lists a firm rating of C- / Strong Sell from a third-party screener, reflecting recent downgrades.

Grades are model outputs, not advice. Market participants should weigh clinical binary risk against potential upside from remaining pipeline assets and partner collaborations.

Forecasts and price target scenarios for IMM.AX stock

Meyka AI’s forecast model projects a yearly price of A$0.35315 and a quarterly view of A$0.45. Against the current close A$0.061, the yearly projection implies an upside of +478.94%. Forecasts are model-based projections and not guarantees.

Scenario targets: conservative short-term price target A$0.10 (liquidity and sentiment recovery), base case 12-month target A$0.35, upside with positive trial or partner news A$0.75. Analysts from Baird and Citizens have issued downgrades and lower price targets following the trial halt, reflecting higher near-term risk.

Final Thoughts

Key takeaways: IMM.AX stock closed at A$0.061 on 16 Mar 2026 after a trial halt that pushed volume to 228,374,534 shares and forced rapid repricing. Fundamentals show negative EPS (-0.06) and a low price-to-book 0.67, but a cash buffer (cash per share A$0.0674) and current ratio 2.97 offer near-term solvency. Technicals lack a clear trend and trade on ASX will remain volatile with wide spreads. Meyka AI’s model projects A$0.35315 in a year, an implied upside of +478.94% versus today’s close; forecasts are model projections and not guarantees. Our view is that IMM.AX remains a high-risk, event-driven biotech play where newsflow and potential partner decisions will determine value. Short-term traders should prioritise liquidity and execution risk; longer-term investors need clarity on pipeline strategy or funding before adding exposure. For live quotes and ongoing coverage see our Meyka AI page for IMM.AX and the linked market reports

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.